Exelixis (NASDAQ:EXEL) Receives Buy Rating from HC Wainwright
HC Wainwright reaffirmed their buy rating on shares of Exelixis (NASDAQ:EXEL – Free Report) in a research note issued to investors on Thursday,Benzinga reports. HC Wainwright currently has a $40.00 price target on the biotechnology company’s stock. Several other equities research analysts have also recently issued reports on EXEL. BMO Capital Markets cut shares of […]
HC Wainwright reaffirmed their buy rating on shares of Exelixis (NASDAQ:EXEL – Free Report) in a research note issued to investors on Thursday,Benzinga reports. HC Wainwright currently has a $40.00 price target on the biotechnology company’s stock. Several other equities research analysts have also recently issued reports on EXEL. BMO Capital Markets cut shares of […]
